Andrew Berens
Stock Analyst at Leerink Partners
(1.31)
# 3,619
Out of 5,006 analysts
96
Total ratings
48.24%
Success rate
-10.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBOT BridgeBio Oncology Therapeutics | Initiates: Outperform | $25 | $12.36 | +102.27% | 1 | Sep 17, 2025 | |
| CELC Celcuity | Maintains: Outperform | $28 → $60 | $50.51 | +18.79% | 2 | Jul 28, 2025 | |
| COGT Cogent Biosciences | Maintains: Outperform | $16 → $18 | $15.76 | +14.21% | 5 | Jul 7, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $125 → $140 | $84.22 | +66.23% | 2 | Jun 24, 2025 | |
| ARVN Arvinas | Downgrades: Market Perform | $10 → $9 | $9.61 | -6.35% | 6 | Jun 2, 2025 | |
| CMPX Compass Therapeutics | Upgrades: Outperform | $4 → $6 | $3.70 | +62.16% | 3 | Apr 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Market Perform | $880 → $762 | $600.00 | +27.00% | 1 | Jan 28, 2025 | |
| OKUR OnKure Therapeutics | Initiates: Outperform | $33 | $2.71 | +1,117.71% | 1 | Dec 5, 2024 | |
| ZYME Zymeworks | Upgrades: Outperform | $10 → $25 | $16.94 | +47.58% | 10 | Nov 7, 2024 | |
| GILD Gilead Sciences | Upgrades: Outperform | $74 → $96 | $112.69 | -14.81% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $60 → $56 | $40.50 | +38.27% | 11 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $86.85 | -10.19% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $48 | $94.29 | -49.09% | 5 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $9.38 | +198.51% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $79 | $85.31 | -7.40% | 12 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $1.61 | +1,577.02% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $25 | $5.90 | +323.73% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $6.05 | +561.16% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $2.27 | +2,851.54% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $7.74 | +158.40% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $7.76 | +222.16% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $11.41 | -29.89% | 7 | Jul 14, 2017 |
BridgeBio Oncology Therapeutics
Sep 17, 2025
Initiates: Outperform
Price Target: $25
Current: $12.36
Upside: +102.27%
Celcuity
Jul 28, 2025
Maintains: Outperform
Price Target: $28 → $60
Current: $50.51
Upside: +18.79%
Cogent Biosciences
Jul 7, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $15.76
Upside: +14.21%
Nuvalent
Jun 24, 2025
Maintains: Outperform
Price Target: $125 → $140
Current: $84.22
Upside: +66.23%
Arvinas
Jun 2, 2025
Downgrades: Market Perform
Price Target: $10 → $9
Current: $9.61
Upside: -6.35%
Compass Therapeutics
Apr 2, 2025
Upgrades: Outperform
Price Target: $4 → $6
Current: $3.70
Upside: +62.16%
Regeneron Pharmaceuticals
Jan 28, 2025
Maintains: Market Perform
Price Target: $880 → $762
Current: $600.00
Upside: +27.00%
OnKure Therapeutics
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $2.71
Upside: +1,117.71%
Zymeworks
Nov 7, 2024
Upgrades: Outperform
Price Target: $10 → $25
Current: $16.94
Upside: +47.58%
Gilead Sciences
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $112.69
Upside: -14.81%
Sep 27, 2024
Downgrades: Market Perform
Price Target: $60 → $56
Current: $40.50
Upside: +38.27%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $86.85
Upside: -10.19%
Apr 17, 2023
Maintains: Outperform
Price Target: $35 → $48
Current: $94.29
Upside: -49.09%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $9.38
Upside: +198.51%
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $85.31
Upside: -7.40%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $1.61
Upside: +1,577.02%
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $5.90
Upside: +323.73%
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $6.05
Upside: +561.16%
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $2.27
Upside: +2,851.54%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $7.74
Upside: +158.40%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $7.76
Upside: +222.16%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $11.41
Upside: -29.89%